Interplay Between Immune Cell Infiltration and Tumor Histological Subtype: A Case of Adrenocortical Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Nov 11

PMID 36358722

Authors

Apollinariya V Bogolyubova

Nano V Pachuashvili

Arina V Tkachuk

Natalia G Mokrysheva

Liliya S Urusova

Affiliations

Soon will be listed here.

Abstract

The analysis of the tumor microenvironment, especially tumor-infiltrated immune cells, is essential for predicting tumor prognosis, clinical outcomes, and therapy strategies. Adrenocortical cancer is a rare nonimmunogenic malignancy in which the importance of the presence of immune cells is not well understood. In our study, we made the first attempt to understand the interplay between the histology of adrenocortical cancer and its immune landscape using cases from The Cancer Genome Atlas database and the Endocrinology Research Centre collection (Moscow, Russia). We showed that the oncocytic variant of adrenocortical cancer is characterized by intensive immune infiltration and better survival, and it is crucial to analyze the effect of immune infiltration independently for each histological variant.

References

Giordano T, Berney D, de Krijger R, Erickson L, Fassnacht M, Mete O . Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol. 2020; 110:50-61. DOI: 10.1016/j.humpath.2020.10.001. View

Huang R, Liu Z, Tian T, Song D, Yan P, Yin H . The construction and analysis of tumor-infiltrating immune cells and ceRNA networks in metastatic adrenal cortical carcinoma. Biosci Rep. 2020; 40(3). PMC: 7103591. DOI: 10.1042/BSR20200049. View

Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G . Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol. 2004; 12(3):231-43. DOI: 10.1177/106689690401200304. View

Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S . Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol. 2014; 27(9):1246-54. DOI: 10.1038/modpathol.2013.230. View

Lam A . Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017; 28(3):213-227. DOI: 10.1007/s12022-017-9484-5. View

de Krijger R, Papathomas T . Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Arch. 2011; 460(1):9-18. PMC: 3267029. DOI: 10.1007/s00428-011-1166-y. View

Thampi A, Shah E, Elshimy G, Correa R . Adrenocortical carcinoma: a literature review. Transl Cancer Res. 2022; 9(2):1253-1264. PMC: 8797314. DOI: 10.21037/tcr.2019.12.28. View

Mete O, Erickson L, Juhlin C, de Krijger R, Sasano H, Volante M . Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022; 33(1):155-196. PMC: 8920443. DOI: 10.1007/s12022-022-09710-8. View

Lo Iacono M, Puglisi S, Perotti P, Saba L, Petiti J, Giachino C . Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies. Cancers (Basel). 2021; 13(21). PMC: 8582505. DOI: 10.3390/cancers13215255. View

10.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

11.

Zheng S, Cherniack A, Dewal N, Moffitt R, Danilova L, Murray B . Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell. 2016; 29(5):723-736. PMC: 4864952. DOI: 10.1016/j.ccell.2016.04.002. View

12.

Pegna G, Roper N, Kaplan R, Bergsland E, Kiseljak-Vassiliades K, Habra M . The Immunotherapy Landscape in Adrenocortical Cancer. Cancers (Basel). 2021; 13(11). PMC: 8199088. DOI: 10.3390/cancers13112660. View

13.

Song S, Park S, Kim S, Suh Y . Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas. Pathol Int. 2004; 54(8):603-10. DOI: 10.1111/j.1440-1827.2004.01669.x. View

14.

Duregon E, Cappellesso R, Maffeis V, Zaggia B, Ventura L, Berruti A . Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. Hum Pathol. 2016; 62:1-7. DOI: 10.1016/j.humpath.2016.09.035. View

15.

Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O . Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021; 39(6):845-865.e7. DOI: 10.1016/j.ccell.2021.04.014. View

16.

Hodgson A, Pakbaz S, Mete O . A Diagnostic Approach to Adrenocortical Tumors. Surg Pathol Clin. 2019; 12(4):967-995. DOI: 10.1016/j.path.2019.08.005. View

17.

Lebastchi A, Kunstman J, Carling T . Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art. J Oncol. 2012; 2012:234726. PMC: 3483813. DOI: 10.1155/2012/234726. View

18.

Marcq E, Siozopoulou V, De Waele J, Van Audenaerde J, Zwaenepoel K, Santermans E . Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017; 6(1):e1261241. PMC: 5283621. DOI: 10.1080/2162402X.2016.1261241. View

19.

Weiss L, Medeiros L, VICKERY JR A . Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989; 13(3):202-6. DOI: 10.1097/00000478-198903000-00004. View

20.

Mearini L, Del Sordo R, Costantini E, Nunzi E, Porena M . Adrenal oncocytic neoplasm: a systematic review. Urol Int. 2012; 91(2):125-33. DOI: 10.1159/000345141. View